BNT162b2 Vaccine Booster and Mortality Due to Covid-19

4th dose of mRNA Covid-19 vaccine significantly increases protection in age 60+

Frontiers COVID-19 vaccine booster hesitancy (VBH) of healthcare professionals and students in Poland: Cross-sectional survey-based study

Effectiveness of CoronaVac, AZD1222, and BNT162b2 vaccine boosters

Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study - The Lancet Respiratory Medicine

Pfizer–BioNTech COVID-19 vaccine - Wikipedia

Clinical efficacy of the fourth dose of the BNT162b2 vaccine in maintenance dialysis patients

Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales - The Lancet

Vaccines, Free Full-Text

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly